The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Serum alpha 2-HS-glycoprotein is an inhibitor of the human insulin receptor at the tyrosine kinase level
Open accessAbstract
The insulin-dependent tyrosine kinase activity (TKA) of the insulin receptor (IR) plays an essential role in insulin signaling. Thus, dysregulation of IR-TKA might be an important element in the states of insulin resistance. A phosphorylated rat hepatic glycoprotein (pp63) acting as an inhibitor of IR-TK has been described. In search of the human homolog of pp63, we isolated a cDNA clone from a human liver lambda gt11 cDNA library. DNA sequence analysis reveals identity with the mRNA product of a human gene AHSG encoding a serum protein, alpha 2-Heremans Scmid-glycoprotein (alpha 2HSG), with heretofore unknown physiological function. Northern blot analysis demonstrates a 1.8-kilobase mRNA in human liver and HepG2 hepatoma cells. alpha 2HSG, purified from human serum, specifically inhibits insulin-stimulated IR autophosphorylation in vitro and in vivo as well as exogenous substrate tyrosine phosphorylation. alpha 2HSG also inhibits both insulin-induced tyrosine phosphorylation of IRS-1 and the association of IRS-1 with the p85 subunit of phosphatidylinositol-3 kinase in H-35 hepatoma cells. alpha 2HSG inhibits insulin-dependent mitogenesis, but does not affect insulin-stimulated induction of the metabolic enzyme tyrosine aminotransferase. alpha 2HSG does not compete with insulin for binding to IR. Finally, the action of alpha 2HSG is specific toward the IR-TK; its effect does not extend to insulin-like growth factor-I-stimulated TKA. Our results allow us to assign a biochemical function for human alpha 2HSG, namely regulation of insulin action at the IR-TK level.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein
Sun, X. J., Rothenberg, P., Kahn, C. R., Backer, J. M., Araki, E., Wilden, P. A., Cahill, D. A., Goldstein, B. J., & White, M. F. (1991) · Nature · doi:10.1038/352073a0 · Cited by 1,574
Freidenberg, G. R., Henry, R. R., Klein, H. H., Reichart, D. R., & Olefsky, J. M. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112789 · Cited by 234
Cited by
Mechanisms of Insulin Action and Insulin Resistance
Petersen, M. C., & Shulman, G. I. (2018) · Physiological Reviews · doi:10.1152/physrev.00063.2017 · Cited by 3,028
Metabolic Syndrome: Updates on Pathophysiology and Management in 2021
Fahed, G., Aoun, L., Bou Zerdan, M., Allam, S., Bou Zerdan, M., Bouferraa, Y., & Assi, H. I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020786 · Cited by 1,441
Hepatokines: Linking nonalcoholic fatty liver disease and insulin resistance
Meex, R. C. R., & Watt, M. J. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.56 · Cited by 631
A liver-derived secretory protein, selenoprotein P, causes insulin resistance
Misu, H., Takamura, T., Takayama, H., Hayashi, H., Matsuzawa-Nagata, N., Kurita, S., Ishikura, K., Ando, H., Takeshita, Y., Ota, T., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.09.015 · Cited by 583
Causes and Metabolic Consequences of Fatty Liver
Stefan, N., Kantartzis, K., & Häring, H.-U. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0009 · Cited by 532
The role of hepatokines in metabolism
Stefan, N., & Häring, H.-U. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.258 · Cited by 500
Ix, J. H., & Sharma, K. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009080820 · Cited by 348
Improved Insulin Sensitivity and Resistance to Weight Gain in Mice Null for the Ahsg Gene
Mathews, S. T., Singh, G. P., Ranalletta, M., Cintron, V. J., Qiang, X., Goustin, A. S., Jen, K.-L. C., Charron, M. J., Jahnen-Dechent, W., & Grunberger, G. (2002) · Diabetes · doi:10.2337/diabetes.51.8.2450 · Cited by 342
Association Between Human Fetuin-A and the Metabolic Syndrome: Data From the Heart and Soul Study
Ix, J. H., Shlipak, M. G., Brandenburg, V. M., Ali, S., Ketteler, M., & Whooley, M. A. (2006) · Circulation · doi:10.1161/circulationaha.105.588723 · Cited by 316
Fetuin-A Induces Cytokine Expression and Suppresses Adiponectin Production
Hennige, A. M., Staiger, H., Wicke, C., Machicao, F., Fritsche, A., Häring, H.-U., & Stefan, N. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001765 · Cited by 282
Fructose and NAFLD: The Multifaceted Aspects of Fructose Metabolism
Jegatheesan, P., & De Bandt, J. (2017) · Nutrients · doi:10.3390/nu9030230 · Cited by 280
Cytokines and abnormal glucose and lipid metabolism
Shi, J., Fan, J., Su, Q., & Yang, Z. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00703 · Cited by 282
“Whereas, injection of recombinant fetuin A into mice reduced insulin sensitivity (179).”
BackgroundFetuin-A and Incident Diabetes Mellitus in Older Persons
Ix, J. H. (2008) · JAMA · doi:10.1001/jama.300.2.182 · Cited by 267
Metabolic adaptation in obesity and type ii diabetes: myokines, adipokines and hepatokines
Oh, K.-J., Lee, D., Kim, W., Han, B., Lee, S., & Bae, K.-H. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms18010008 · Cited by 210
Yang, S. J., Hwang, S. Y., Choi, H. Y., Yoo, H. J., Seo, J. A., Kim, S. G., Kim, N. H., Baik, S. H., Choi, D. S., & Choi, K. M. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0620 · Cited by 191
Dasgupta, S., Bhattacharya, S., Biswas, A., Majumdar, S. S., Mukhopadhyay, S., Ray, S., & Bhattacharya, S. (2010) · Biochemical Journal · doi:10.1042/bj20100330 · Cited by 168
Fetuin-A: A novel link between obesity and related complications
Trepanowski, J. F., Mey, J., & Varady, K. A. (2015) · International Journal of Obesity · doi:10.1038/ijo.2014.203 · Cited by 161
Gerst, F., Wagner, R., Kaiser, G., Panse, M., Heni, M., Machann, J., Bongers, M. N., Sartorius, T., Sipos, B., Fend, F., et al. (2017) · Diabetologia · doi:10.1007/s00125-017-4385-1 · Cited by 151
A simple and robust serum-free media for the proliferation of muscle cells
Skrivergaard, S., Young, J. F., Sahebekhtiari, N., Semper, C., Venkatesan, M., Savchenko, A., Stogios, P. J., Therkildsen, M., & Rasmussen, M. K. (2023) · Food Research International · doi:10.1016/j.foodres.2023.113194 · Cited by 93
Hepatokines and non-alcoholic fatty liver disease
Lebensztejn, D. M., Flisiak-Jackiewicz, M., Białokoz-Kalinowska, I., Bobrus-Chociej, A., & Kowalska, I. (2016) · Acta Biochimica Polonica · doi:10.18388/abp.2016_1252 · Cited by 90
“This observation was also confirmed in humans (Srinivas et al., 1993; Mori et al., 2011).”
ResultThe RNA-binding protein vigilin regulates VLDL secretion through modulation of Apob mRNA translation
Mobin, M. B., Gerstberger, S., Teupser, D., Campana, B., Charisse, K., Heim, M. H., Manoharan, M., Tuschl, T., & Stoffel, M. (2016) · Nature Communications · doi:10.1038/ncomms12848 · Cited by 55
Role of exercise-induced hepatokines in metabolic disorders
Ennequin, G., Sirvent, P., & Whitham, M. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00433.2018 · Cited by 54
Goustin, A. S., Derar, N., & Abou-Samra, A. B. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2012.12.011 · Cited by 51
Self-citation(2020) · Advances in clinical chemistry · doi:10.1016/bs.acc.2019.07.012 · Cited by 46
Ramírez-Vélez, R., García-Hermoso, A., Hackney, A. C., & Izquierdo, M. (2019) · Lipids in Health and Disease · doi:10.1186/s12944-019-0962-2 · Cited by 37
Geroldi, D., Minoretti, P., Bianchi, M., Di Vito, C., Reino, M., Bertona, M., & Emanuele, E. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2005.06.014 · Cited by 18
Metadata
- Authors
- Srinivas, P. R.
- Venue
- Molecular Endocrinology
- Publisher
- The Endocrine Society
- Published
- 1993-11-01
- Volume
- 7
- Issue
- 11
- Pages
- 1445-1455
- ISSN
- 0888-8809 (ISSN-L)
- OpenAlex
- W2081010930
- Cited by
- 243
- References
- 2
- FWCI
- 1.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.